High-throughput chromatography in bioprocess analytics

High-Throughput Chromatography News

High-throughput chromatography in bioprocess analytics
United States Latest News,United States Headlines

Understand bioprocess analytics with high-throughput chromatography optimization.

Sponsored Content by LonzaReviewed by Ify IsiborApr 30 2026 Developing control strategies and manufacturing processes for new molecular formats of biologics is increasingly challenging.

NMFs represent a wide range of molecules, from antibody-based biologics such as Fc-fusion proteins and bispecific antibodies to hormones and blood factors fused to other motifs. These diverse classes of molecules often exhibit unknown properties and behave less predictably during development, particularly compared to monoclonal antibodies. As a CDMO, rapidly advancing downstream process development solutions for these therapeutic molecules cost-effectively and on schedule is of key importance to Lonza’s customers.

The company has a flexible approach that makes use of its antibody platform downstream process where appropriate, and augments its development process with high-throughput approaches to accommodate the specific challenges expected when working with particular molecules. During his PhD, Lonza’s Nicholas Field dedicated three years of his professional life to high-throughput chromatography methodologies, including automation and purification chemistry.

Since leaving academia, his work at Lonza has centered around translating his experience and knowledge into developing a portfolio of high-throughput capabilities. These capabilities are then made accessible to the company’s teams to support customer program delivery. Lonza has designed its high-throughput purification development capabilities around four cornerstones: technology, standardization, training and competence, and flexibility. Technology in high-throughput chromatography Lonza has invested in three automated liquid handling systems at its Slough site.

These systems can run liquid-phase solubility screens and assess resin-filled plates and 600 µL chromatography mini columns . These powerful hardware capabilities work in conjunction with a third-party software solution, enabling the integrated planning, operation, and analysis of these experiments, simplifying their execution and ensuring efficient chromatography process development . Figure 1. Automated liquid handling system injecting liquid phase into eight 600 µL pre-packed chromatography mini columns.

Figure An example workflow for the development of a mixed-mode chromatography step using high-throughput techniques and a design of experiments approach. Image Credit: Lonza Standardization in chromatography chemistries Working with talented scientists within the Lonza Purification Development team, the company has developed a suite of standardized screens suitable for developing various chromatography chemistries, including ion exchange, hydrophobic interaction, affinity, and mixed-mode chromatography.

Lonza has also developed standard screens to help investigate products’ solubility and stability under different liquid-phase conditions. These methods offer the company’s customers a toolbox of approaches to support the development of purification solutions for a specific molecule of interest. Training and competence in purification development If not completed by properly trained and competent operators, HT experiments can be complicated and error-prone.

This is primarily due to the complex nature of the equipment and control software, and to the large number of conditions tested at a given time. Lonza has set up a sub-team of specialized HT operators to support these projects. These operators have been specifically trained on these screens, running them regularly to ensure competence and familiarity.

Working with a smaller, more focused team also helps build competence because each member runs the screen more often than they would on a larger team. Subject Matter Experts are also present within the department. These experts have greater experience, allowing them to design non-standard experiments more effectively or troubleshoot issues.

Flexibility for new molecular format products The inherent nature of new molecular format biologics, along with the challenges posed by their characteristics and product-related impurities, means it will not always be possible to achieve the desired outcome using a standardized screen. Flexibility is required in these cases in order to ensure a successful outcome. Lonza’s cornerstone of flexibility rests on the company’s other capabilities in the HT space.

For instance, its use of third-party software helps simulate bespoke experiments before performing them, thereby maximizing the likelihood of a successful outcome. The company’s toolbox of screening methods also provides a comprehensive yet flexible suite of options suitable for exploring alternative operating conditions and chromatography chemistries. Lonza’s standard screens offer a useful jumping-off point for augmentation when needed in specific programs, and the company’s trained operators and SMEs can work together to design bespoke approaches when necessary.

Nicholas Field highlights the rewards of developing these pioneering purification solutions and the high-throughput screening capabilities now available at Lonza. These solutions were developed as a collaborative effort involving Lonza’s R&D department, third-party suppliers, and Lonza Purification Development scientists who performed the essential initial lab work to test and refine these capabilities.

Implementing and applying these four cornerstones results in a lasting foundation for continued progress in purification development and the future success of downstream process development, supporting Lonza’s customers and the therapies being developed for their patients. Acknowledgments Produced from materials originally authored by Nicholas Field, Ph. D., from Lonza. About Lonza Lonza is one of the world’s largest contract development and manufacturing organizations dedicated to serving the healthcare industry.

Working across five continents, our global team of approximately 20,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. We support our customers in bringing life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology, and lean manufacturing. Our company generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025. Find out more at www.lonza.com.

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NewsMedical /  🏆 19. in UK

 

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Manchester City set for ‘very busy’ summer transfer window after targeting ‘high-quality players’Manchester City set for ‘very busy’ summer transfer window after targeting ‘high-quality players’The inside track on the football stories that matter
Read more »

Gang who stole high-performance cars in Surrey and Sussex jailedGang who stole high-performance cars in Surrey and Sussex jailedPolice say the offenders broke into homes in Stoneleigh and Copthorne to take keys and steal cars.
Read more »

City regulator reviewing whether APRs help consumers understand borrowing costsCity regulator reviewing whether APRs help consumers understand borrowing costsThe Financial Conduct Authority said that to help people navigate their financial lives, it is asking for views on whether there is a better way.
Read more »

Harry Styles' Love Evolution: From High-Profile Romances to Settling Down with Zoe KravitzHarry Styles' Love Evolution: From High-Profile Romances to Settling Down with Zoe KravitzHarry Styles, once known for his string of high-profile relationships, has reportedly shifted his focus towards a more stable future, with rumors of an engagement to Zoe Kravitz after just eight months of dating. This article explores his journey from teenage heartthrob to a man ready for marriage and family.
Read more »

Young Engineer Kills High School Sweetheart Before Taking Own Life in Pennsylvania TragedyYoung Engineer Kills High School Sweetheart Before Taking Own Life in Pennsylvania TragedyA 26-year-old engineer shot his wife, a neurocritical care physician assistant, at her father’s home before committing suicide in the woods nearby. The couple had been married for 19 months and shared a long history dating back to high school. Authorities are investigating the motive behind the murder-suicide.
Read more »

Tailored downstream solutions for protein-based therapeuticsTailored downstream solutions for protein-based therapeuticsThis article helps readers understand tailored downstream solutions for protein-based therapeutics.
Read more »



Render Time: 2026-05-05 20:14:19